Navigation Links
Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at American College of Gastroenterology Annual Scientific Meeting
Date:9/9/2008

are evaluating our lead MEK inhibitor, RDEA119, in a Phase 1 study in advanced cancer patients, and have completed a Phase 1 study in normal healthy volunteers as a precursor to trials in patients with inflammatory diseases. Lastly, we have evaluated our second-generation MEK inhibitor for the treatment of cancer and inflammatory diseases, RDEA436, in a human micro-dose pharmacokinetic study and have selected it for clinical development.

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding our goals, including the expected properties and benefits of RDEA806, RDEA427, RDEA594, RDEA119, RDEA436 and our other compounds and the results of preclinical, clinical and other studies. Risks that contribute to the uncertain nature of the

forward-looking statements include: risks related to the outcome of preclinical and clinical studies, risks related to regulatory approvals, delays in commencement of preclinical and clinical studies, and costs associated with our drug discovery and development programs and business development activities. These and other risks and uncertainties are described more fully in our most recently filed SEC documents, including our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q, under the headings "Risk Factors." All forward-looking statements contained in this press release speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.


'/>"/>
SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout, RDEA594, Into Phase 1 Clinical Trial
2. Ardea Biosciences Presents Phase 2a Antiviral Activity Data for Lead HIV Candidate, RDEA806 at XVII International AIDS Conference
3. Ardea Biosciences Reports Additional Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating Up to 1.9 Log Reduction in Plasma Viral Load with Once-Daily Dosing
4. Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program
5. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
6. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
7. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
8. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
9. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
10. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
11. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)... Auf seiner am ... veranstalteten F&E-Tagung meldete Astellas Fortschritte im ... Forschungsrahmenprogramms. Die Tagung bot Astellas die Gelegenheit, ... Programme und die Konzernstrategie des Unternehmens zu ... aktuelle Meldungen zu den Astellas-Initiativen in den ...
(Date:7/13/2014)... 13, 2014  Eli Lilly and Company (NYSE: ... its non-clinical study in genetically engineered mice examining ... beta-amyloid antibody N3pG and beta-secretase inhibitor BACE (LY2811376). ... effective in removing clumps of amyloid-beta protein in ... to lead to Alzheimer,s disease (AD) – than ...
(Date:7/11/2014)... LOS ANGELES , July 11, 2014 /PRNewswire-iReach/ ... of e-liquid, a vegetable-glycol solution for use in ... one of the active ingredients in cannabis, cannabidiol ... in personal vaporizer devices, and other vaporizer technology. ... Cannabis naturally contains 483 different compounds ...
Breaking Medicine Technology:Astellas erörtert Pipeline-Fortschritte auf F&E-Tagung 2Astellas erörtert Pipeline-Fortschritte auf F&E-Tagung 3Astellas erörtert Pipeline-Fortschritte auf F&E-Tagung 4New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 2New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 3VAPETEK Releases CBD-Infused eLiquid For The Consumer Market 2
(Date:7/13/2014)... 2014 Chromatography system is a ... various types of biological samples such as air ... mixture into two phase, namely mobile phase and ... run over the stationary phase, followed by the ... provide the separation of mixture. Chromatography system plays ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 Micro irrigation ... ensure proper water dispersal as wells as to maintain ... agriculture is projected to become a dominant revenue generator ... sophisticated methods to reduce resource costs has led to ... and plantations, and has further caused massive demand for ...
(Date:7/13/2014)... According to a new market ... by Component (processor, GPU, DSP, connectivity), Technology Node ... Geography - Forecast and Analysis to 2014-2020", published ... Computing Market is expected to reach $61.70 Billion ... from 2014 to 2020. , Browse 71 market ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 The Pearland, Texas ... ranging in age from four months to 12 years of ... karate classes to birthday parties and Summer Camps, is now ... Little Gym of Pearland after spending over six years ... roles, including Gym Director. , Berry has over ten ...
(Date:7/13/2014)... 13, 2014 Max International ... Mullin, will be the featured guest at its Charity ... Puerto Rico. Attendees will learn about Max’s health ... two exhibition basketball games and perform in a 3 ... of health- and energy-boosting supplements , has recently announced ...
Breaking Medicine News(10 mins):Health News:North America Chromatography Systems Market Is Expected to Reach $6593.4 Million by 2018 - New Report by MicroMarket Monitor 2Health News:North America Chromatography Systems Market Is Expected to Reach $6593.4 Million by 2018 - New Report by MicroMarket Monitor 3Health News:Agricultural Micro Irrigation System Market is Expected to Grow at a CAGR of 18.1%, from 2013 to 2018 - New Report by MicroMarket Monitor 2Health News:Agricultural Micro Irrigation System Market is Expected to Grow at a CAGR of 18.1%, from 2013 to 2018 - New Report by MicroMarket Monitor 3Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 4Health News:The Little Gym of Pearland, TX Now Under New Ownership and Management 2Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 2Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 3Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 4
... HealthDay Reporter , THURSDAY, Nov. 4 (HealthDay News) ... cut mortality rates in older, current or former heavy smokers ... Given the large numbers of Americans who fall ill from ... 20 percent drop in deaths could be significant, experts noted. ...
... Nine years ago, scientists at Cedars-Sinai,s Maxine Dunitz Neurosurgical ... makeup of the most aggressive type of brain tumors, ... specific protein called laminin-411 plays a major role in ... support its growth and spread. But technology did not ...
... Most mutations in the genes of the Salmonella ... And this is the case regardless whether they lead to ... by Uppsala University scientists in an article being published today ... have examined the impact of mutations on the rate of ...
... News) -- During cold weather, the use of extra ... lead to dangerous overheating and increase the risk of ... Infants are sensitive to extremes in temperatures and have ... that multiple layers of clothing, heavy clothing, heavy blankets ...
... named Vinita Goyal, MD, MPH, its newest Women,s Reproductive ... Program was initiated in 1998 by the Eunice Kennedy ... (NICHD), in collaboration with the National Institutes of Health ... Infants and Brown University were awarded one of the ...
... HealthDay Reporter , THURSDAY, Nov. 4 (HealthDay News) ... in day care facilities that get meals and snacks through ... says. The report from the Institute of Medicine calls ... sugar. Many of the most needy children and adults ...
Cached Medicine News:Health News:CT Scans Seem to Lower Lung Cancer Death Rates 2Health News:CT Scans Seem to Lower Lung Cancer Death Rates 3Health News:CT Scans Seem to Lower Lung Cancer Death Rates 4Health News:Cedars-Sinai 'nano-drug' hits brain-tumor target found in 2001 2Health News:Cedars-Sinai 'nano-drug' hits brain-tumor target found in 2001 3Health News:Unexpectedly small effects of mutations in bacteria bring new perspectives 2Health News:Overheating in Infants Can Lead to SIDS, Experts Warn 2Health News:WRHR scholar to study contraception availability for female veterans 2Health News:WRHR scholar to study contraception availability for female veterans 3Health News:WRHR scholar to study contraception availability for female veterans 4Health News:U.S. Government Food Program Needs Improving: Report 2Health News:U.S. Government Food Program Needs Improving: Report 3
... features a low molecular weight ... viscosity you need to achieve ... small-incision surgery. The sustained viscoelastic ... depth for safe, ample working ...
... CoEase is designed to provide excellent protection ... unique advantage of being closer to an ... This allows CoEase to maintain viscosity ... best of both worlds for superb performance ...
... ophthalmic viscosurgical device is a ... by high molecular weight, high ... It provides excellent space maintenance, ... easily removed. It is available ...
... DigitalCameras permit fundus imaging and documentation ... without any need for eyepieces guarantees ... Image recording and display is an ... the ophthalmoscope principle of modern fundus ...
Medicine Products: